Article
Rhaponticin suppresses the stemness phenotype of gastric cancer stem-like cells CD133+/CD166 + by inhibiting programmed death-ligand 1.
BMC gastroenterology - 21 Nov 2024
Li Yulong, Zhang Yu, Tang Jialin
Abstract excerpt
BACKGROUND: Gastric cancer stem cells (GCSCs) are key contributors to tumorigenesis, recurrence and metastasis, complicating gastric cancer (GC) treatment. Rhaponticin (RA), a potential novel anticancer drug, has unexplored effects on GCSCs. METHODS: GCSCs were isolated using CD133 and CD166 markers with magnetic bead separation method and then evaluated their response to the IC50 concentrations of RA...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
